PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at investor.zimvie.com
About ZimVie
ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Media Contact Information:
ZimVie
Allison Johnson • This email address is being protected from spambots. You need JavaScript enabled to view it.
(774) 266-8046
ZimVie
Grace Flowers • This email address is being protected from spambots. You need JavaScript enabled to view it.
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Marissa Bych • This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$13.50 |
| Daily Change: | -0.45 -3.23 |
| Daily Volume: | 196,581 |
| Market Cap: | US$372.600M |
October 30, 2024 October 29, 2024 August 01, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
